It comes shortly after AbbVie offered $10.1 billion to buy ImmunoGen and its marketed ovarian cancer drug Elahere (mirvetuximab soravtansine), and a pipeline of other antibody-drug conjugates for ...

Among some other larger deals, AbbVie acquired ImmunoGen last year ... see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. 5 Stocks Set to Double Each was handpicked ...

However, the increase in ABBV stock has been far from consistent. Returns for the stock were 32% in 2021, 24% in 2022, and 0% in 2023. In comparison, returns for the S&P 500 have been 27% in 2021, -19 ...

AbbVie's stock has risen to an all-time high, raising the question of whether it's still a good buy. Read why I’m maintaining ...

We recently compiled a list of the 10 Best Cancer Stocks To Buy Now. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other cancer stocks.

Analyst Terence Flynn from Morgan Stanley maintained a Buy rating on AbbVie (ABBV – Research Report) and keeping the price target at ...

AbbVie is also looking at inorganic growth. After its acquisition of Allergan in 2020, it acquired ImmunoGen for $10.1 billion this year, giving it rights to Elahere — an ovarian cancer ...

The company recently strengthened its oncology presence by acquiring ImmunoGen for $10.1 billion ... future growth once the Humira decline stabilizes. CFRA maintains a "buy" rating on AbbVie with a ...

Among some other larger deals, AbbVie acquired ImmunoGen last year, which added the latter’s ... You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Want the latest ...